Section 4 of 6
Clinical evidence
416 evidence topics · 50 sources
Study summaries
Voyage
Objective
Objective: efficacy and safety of a single 100 µg dose of DT120 versus placebo
Part B objective: maintenance of efficacy and retreatment patterns
Location and study date
Sites: approximately 35 in the United States
Registered locations: 34 sites in the United States
Registered study dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2024-12-11” |
| Primary completion (actual) | “2026-07-15” |
| Study completion (estimated) | “2027-04” |
| Recruitment status | “Active, not recruiting” |
First participant dosed: December 2024
Topline results (Part A) reported: August 12, 2026
Topline timing: early third quarter of 2026, February to May 2026, superseded in August 2026
Topline timing: second quarter of 2026, January 2026, superseded in February 2026
Topline timing: first half of 2026, March to November 2025, superseded in January 2026
Study design
Design: phase 3, multicenter, randomized, double-blind, placebo-controlled
Part A and Part B: 12-week parallel-group period and 40-week extension
Randomization: 1:1 to DT120 or placebo
Two-arm framework without a low-dose comparator
Masking: participants and treating clinicians, identical placebo tablet
Central raters blinded to treatment assignment and visit number
Expectancy and perceived treatment assessment
Adaptive design: blinded interim sample size re-estimation
Part B: symptom-triggered open-label treatment
Part B: follow-up observation and retreatment threshold
“GAD-7 (ePRO): biweekly” (opens the source at this quote in a new tab)
“HAM-A (central rater): monthly or when GAD-7 ≥10” (opens the source at this quote in a new tab)
“Eligible for open-label treatment if HAM-A ≥16” (opens the source at this quote in a new tab)
“Up to 4 open-label doses of DT120 ODT 100 µg” (opens the source at this quote in a new tab)
Eligibility criteria
Exclusion criteria: registry record
Diagnosis confirmed by the Mini-International Neuropsychiatric Interview
Key inclusion criteria: Voyage and Panorama
Key exclusion criteria: Voyage and Panorama
Prior psychedelic use criterion amended to any lifetime use
Concomitant medications with interaction potential or anxiolytic or antidepressant effects
Treatment
Single administration of DT120 ODT 100 µg in Part A
Dosing session monitors and psychotherapy
End-of-session checklist: hourly from hour 5 after dosing
Required monitoring period in the pivotal studies: 8 hours
Study outcomes
Rationale for using hamilton anxiety rating scale total score as the primary endpoint
Primary endpoint: change in HAM-A total score at Week 12
Week 12 timepoint based on the durability observed in the phase 2b study
HAM-A: 14-item clinician-rated scale, range 0 to 56
Minimal clinically important difference and dose selection from the phase 2b study
“The minimal clinically important difference was 2.5 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings support the selection of 100-µg dose of MM120 for pivotal trials to assess its efficacy, durability, and safety in the treatment of GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoints: HAM-A response, remission, and mild or better at Week 12
Clinical Global Impression-Severity: range 1 to 7
Registered secondary endpoints: patient-reported outcomes, functioning, and quality of life
Registered secondary endpoints: retreatment in Part B
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled: 214 participants randomized 1:1
Sample size re-estimation: no increase required
Analyzed: all randomized participants in the intention-to-treat population
| Arm | Randomized | Analysis population |
|---|---|---|
| DT120 ODT | “n=107” | “100% included in ITT population” |
| Placebo ODT | “n=107” | “100% included in ITT population” |
Planned enrollment: approximately 200 participants, December 2024 to February 2026, superseded in May 2026
Description of analysis sets
Primary analysis: mixed-effects model for repeated measures with reference-based imputation, ITT population
Multiplicity control: hierarchical testing of key secondary endpoints
Safety population: Part A through Week 12
Subgroup analyses: same model as the primary analysis
Part B interim analysis: extension population and ITT Part A+B population
Results
Participant disposition
Part A completion
| Arm | Randomized | Completed Part A |
|---|---|---|
| DT120 ODT | “n=107” | “90% completed Part A” |
| Placebo ODT | “n=107” | “88% completed Part A” |
Part B interim disposition as of July 15, 2026
| Part A arm | Part B extension population | Through Week 28 | Through Week 36 | Through Week 52 |
|---|---|---|---|---|
| DT120 ODT | “n=90” | “Through Week 28 (n=44)” | “Through Week 36 (n=31)” | “Through Week 52 (n=14)” |
| Placebo ODT | “n=87” | “Through Week 28 (n=53)” | “Through Week 36 (n=30)” | “Through Week 52 (n=8)” |
Baseline characteristics
Demographics and baseline characteristics: ITT population
| Characteristic | DT120 ODT (n = 107) | Placebo ODT (n = 107) | Overall (N = 214) |
|---|---|---|---|
| Age, mean (range), years | “42 (21–72)” | “43 (20–67)” | “42 (20–72)” |
| Female, n (%) | “63 (59)” | “74 (69)” | “137 (64)” |
| Male, n (%) | “44 (41)” | “33 (31)” | “77 (36)” |
| White, n (%) | “78 (73)” | “77 (72)” | “155 (72)” |
| Black or African American, n (%) | “9 (8)” | “19 (18)” | “28 (13)” |
| Asian, n (%) | “8 (7)” | “9 (8)” | “17 (8)” |
| Baseline HAM-A score, mean (SD) | “28.4 (5.9)” | “27.4 (5.5)” | “27.9 (5.7)” |
| Moderate GAD (HAM-A <24), n (%) | “26 (24)” | “28 (26)” | “54 (25)” |
| Severe GAD (HAM-A ≥24), n (%) | “81 (76)” | “79 (74)” | “160 (75)” |
| Baseline CGI-S score, mean (SD) | “4.6 (0.6)” | “4.6 (0.6)” | “4.6 (0.6)” |
| Past use of any psychedelic, n (%) | “18 (17)” | “27 (25)” | “45 (21)” |
| Past LSD use, n (%) | “10 (9)” | “9 (8)” | “19 (9)” |
| No past GAD medications, n (%) | “35 (33)” | “36 (34)” | “71 (33)” |
| One past GAD medication, n (%) | “31 (29)” | “34 (32)” | “65 (30)” |
| Two or more past GAD medications, n (%) | “41 (38)” | “37 (35)” | “78 (36)” |
| Comorbid MDD, n (%) | “43 (40)” | “37 (35)” | “80 (37)” |
| Years since GAD diagnosis, mean (SD) | “11.1 (10.1)” | “12.9 (11.6)” | “12.0 (10.9)” |
| Years since onset of GAD symptoms, mean (SD) | “21.9 (13.7)” | “25.7 (14.4)” | “23.8 (14.1)” |
Severity categories and psychedelic definitions
Baseline MADRS score
| Characteristic | DT120 ODT (n=107) | Placebo ODT (n=107) | Overall (n=214) |
|---|---|---|---|
| MADRS score, mean (SD) | “13.6 (4.6)” | “13.5 (4.4)” | “13.5 (4.5)” |
Characteristics at Part B entry: interim analysis
Efficacy results
Primary and key secondary endpoints: Part A
| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
|---|---|---|---|
| HAM-A: LS mean change at Week 12 (primary) | “-11.6” | “-6.2” | “-5.4 (p<.0001)” |
| CGI-S: LS mean change at Week 12 (key secondary) | “-1.0” | “-0.4” | “-0.6 (p<.0001)” |
| HAM-A: LS mean change at Week 1 (key secondary) | “-11.9” | “-4.2” | “-7.7 (p<.0001)” |
| CGI-S: LS mean change at Day 2 (key secondary) | “-1.0” | “-0.2” | “-0.8 (p<.0001)” |
Response, remission, and mild or better at Week 12
| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
|---|---|---|---|
| HAM-A response rate (≥50%) at Week 12 | “43%” | “16%” | “27% (p<0.0001)” |
| HAM-A remission rate (≤7) at Week 12 | “14%” | “4%” | “10% (p=0.0222)” |
| HAM-A mild or better (<16) at Week 12 | “51%” | “23%” | “28% (p<0.0001)” |
HAM-A change from baseline by visit
| Visit | DT120 ODT: change from baseline | Improvement over placebo |
|---|---|---|
| Week 1 | “Week 1: −11.9 points” | “Week 1: −7.7 points” |
| Week 4 | “Week 4: −12.5 points” | “Week 4: −6.8 points” |
| Week 8 | “Week 8: −12.1 points” | “Week 8: −5.5 points” |
| Week 12 | “Week 12: −11.6 points” | “Week 12: −5.4 points” |
CGI-S change from baseline by visit
| Visit | DT120 ODT: change from baseline | Improvement over placebo |
|---|---|---|
| Day 2 | “Day 2: −1.0 points” | “Day 2: −0.8 points” |
| Week 1 | “Week 1: −1.4 points” | “Week 1: −1.1 points” |
| Week 4 | “Week 4: −1.3 points” | “Week 4: −0.7 points” |
| Week 8 | “Week 8: −1.1 points” | “Week 8: −0.6 points” |
| Week 12 | “Week 12: −1.0 points” | “Week 12: −0.6 points” |
Subgroup analyses: placebo-adjusted change in HAM-A at Week 12
| Subgroup | Placebo-adjusted change in LS mean (SE) |
|---|---|
| All participants | “−5.4 (1.0)” |
| Time since GAD symptoms began <22 years (n = 107) | “−5.9 (1.4)” |
| Time since GAD symptoms began ≥22 years (n = 107) | “−4.7 (1.5)” |
| Previous GAD medications <2 (n = 136) | “−4.2 (1.2)” |
| Previous GAD medications ≥2 (n = 78) | “−5.6 (1.7)” |
| Male (n = 77) | “−7.1 (1.7)” |
| Female (n = 137) | “−5.5 (1.2)” |
Part B interim: response, remission, and mild or better through Week 28 among participants given DT120 in Part A
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse event overview: Part A safety population
| Adverse event | DT120 ODT (n = 107) | Placebo ODT (n = 107) |
|---|---|---|
| Any TEAE, n (%) | “106 (99)” | “74 (69)” |
| Mild | “65 (61)” | “49 (46)” |
| Moderate | “41 (38)” | “24 (22)” |
| Severe | “0” | “1 (1)” |
| Any study drug–related TEAE, n (%) | “102 (95)” | “51 (48)” |
| Any AESI, n (%) | “100 (93)” | “30 (28)” |
| Any treatment-emergent SAE, n (%) | “0” | “3 (3)” |
| Any TEAE leading to discontinuation, n (%) | “1 (1)” | “0” |
| Any TEAE leading to death, n (%) | “0” | “0” |
Adverse events of special interest: topline presentation value
| Adverse event | DT120 ODT (n=107) | Placebo ODT (n=107) |
|---|---|---|
| Any Adverse Event of Special Interest (AESI) | “100 (94%)” | “30 (28%)” |
Severity, timing, and most common adverse events
TEAEs with incidence of 10% or more, on the dosing day and after it
| TEAE | Dosing day: DT120 ODT (n=107) | Dosing day: placebo ODT (n=107) | After dosing day: DT120 ODT (n=107) | After dosing day: placebo ODT (n=107) |
|---|---|---|---|---|
| Illusion | “80 (75%)” | “11 (10%)” | “2 (2%)” | “0” |
| Nausea | “41 (38%)” | “9 (8%)” | “3 (3%)” | “3 (3%)” |
| Euphoric mood | “28 (26%)” | “4 (4%)” | “0” | “0” |
| Headache | “26 (24%)” | “7 (7%)” | “12 (11%)” | “7 (7%)” |
| Feeling abnormal | “21 (20%)” | “3 (3%)” | “0” | “0” |
| Disorientation | “19 (18%)” | “2 (2%)” | “1 (1%)” | “0” |
| Dizziness | “14 (13%)” | “5 (5%)” | “1 (1%)” | “1 (1%)” |
| Crying | “13 (12%)” | “4 (4%)” | “0” | “0” |
| Thinking abnormal | “12 (11%)” | “1 (1%)” | “0” | “0” |
| Paraesthesia | “12 (11%)” | “4 (4%)” | “0” | “0” |
| Feeling of body temperature change | “12 (11%)” | “1 (1%)” | “0” | “0” |
| Anxiety | “11 (10%)” | “2 (2%)” | “3 (3%)” | “0” |
| Feeling of relaxation | “8 (8%)” | “12 (11%)” | “1 (1%)” | “0” |
| Hallucination, visual | “9 (8%)” | “2 (2%)” | “1 (1%)” | “0” |
| Insomnia | “7 (7%)” | “0” | “1 (1%)” | “6 (6%)” |
| Emotional disorder | “6 (6%)” | “1 (1%)” | “1 (1%)” | “0” |
Suicidality: Columbia-Suicide Severity Rating Scale
Serious adverse events across DT120 studies, including Part B of Voyage, as of September 14, 2026
Serious adverse events across DT120 studies, August 2026, superseded in November 2026
End-of-session checklist clearance: topline announcement, August 2026
End-of-session checklist clearance: Psych Congress poster, September 2026
Study limitations
Summary
- Publication status: results come from company topline announcements, presentations, and filings and from a report of the Voyage topline results; one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results.
- Functional unblinding: Voyage used a two-arm design of DT120 100 µg versus placebo without the 50 µg low-dose comparator used in Panorama. Study drug-related TEAEs occurred in 95% of participants receiving DT120 and 48% receiving placebo, and illusion occurred on the dosing day in 75% and 10%. Baseline expectancy and perceived treatment were recorded; the cited disclosures report no results of these assessments. Central HAM-A raters were blinded to treatment assignment and visit number. Past psychedelic use was reported by 21% of participants.
- Duration and dosing: the controlled comparison covers 12 weeks after a single dose. Part B is open label, and its results come from an interim analysis as of July 15, 2026, with 37 participants who received DT120 in Part A contributing HAM-A data at Week 28.
- Comparator: placebo was the only comparator; no active GAD treatment was included. The placebo group improved by 6.2 points on HAM-A at Week 12.
- Generalizability: participants were 18 to 74 years of age at approximately 35 sites in the United States, and people taking medications with anxiolytic or antidepressant effects that could not be discontinued, people with a personal or first-degree family history of psychotic or bipolar disorder, people with current alcohol or substance use disorder, and people in systematic psychotherapy within 4 weeks before screening were excluded.
- Outcomes not reported in the cited disclosures: registered patient-reported, functioning, quality of life (PGI-S, WPAI-SHP, EQ-5D-5L), and sexual functioning (CSFQ-14) endpoints. The sponsor stated that Part B safety data are expected to be shared in a future presentation.
- Discrepancies between sources: the share of participants clearing the end-of-session checklist by hour 8 is 92% in the topline announcement and 90% in the poster, and adverse events of special interest with DT120 are 100 (94%) in the topline presentation and 100 (93) in the poster.
Panorama
Objective
Registered study purpose and official title
Objective stated by the sponsor
Objectives of Part A and Part B across the phase 3 trials
Location and study date
Study dates in the registry
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2025-01-29” |
| Primary completion (actual) | “2026-08-13” |
| Study completion (estimated) | “2027-05” |
| First posted | “2025-02-05” |
| Last update posted | “2026-09-04” |
Registered locations
Registry status and results posting
Study centers reported by the sponsor
EU member state decision, trial start, and recruitment dates
| Member state | Decision date | Trial start | Recruitment start | Recruitment end |
|---|---|---|---|---|
| Germany | “19/02/2025” | “21/08/2025” | “04/09/2025” | “15/05/2026” |
| France | “20/02/2025” | “26/09/2025” | “22/12/2025” | “15/05/2026” |
| Czech Republic | “24/02/2025” | “20/08/2025” | “02/09/2025” | “15/05/2026” |
| Poland | “02/03/2025” | “25/09/2025” | “03/10/2025” | “15/05/2026” |
First participant dosed, January 2025
Topline results of Part A reported September 14, 2026
Topline timing: September 2026, August 2026, superseded by results reported in September 2026
Topline timing: late third quarter of 2026, April 2026, superseded in August 2026
Topline timing: second half of 2026, January 2025, superseded in April 2026
Study design
Phase 3 randomized, double-blind, placebo-controlled design with an open-label extension
Randomization ratio and the 50 µg arm
Statistical comparisons limited to 100 µg versus placebo
Registry design fields
| Field | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Triple” |
| Phase | “Phase 3” |
| Arm 1 | “Placebo Comparator: Arm 1 - Placebo” |
| Arm 2 | “Sham Comparator: Arm 2 - 50µg DT120” |
| Arm 3 | “Experimental: Arm 3 - 100µg DT120” |
Adaptive design with blinded sample size re-estimation
Blinding, central raters, and dosing session monitors
Symptom-triggered open-label treatment in Part B
Eligibility criteria
Registered inclusion and exclusion criteria
“Diagnosis of GAD per DSM-5” (opens the source at this quote in a new tab)
“Male or female aged 18 to 74” (opens the source at this quote in a new tab)
“HAM-A Total Score ≥20” (opens the source at this quote in a new tab)
“Any clinically significant unstable illness” (opens the source at this quote in a new tab)
Key inclusion and exclusion criteria for Voyage and Panorama
Amendment of the prior psychedelic use criterion
Exclusion of a current major depressive episode
Age range in the EU trial record
Treatment
Study drug and placebo in the registry
Single dose in Part A
| Arm | Part A treatment |
|---|---|
| DT120 ODT 100 µg | “DT120 ODT 100 µg” |
| DT120 ODT 50 µg | “DT120 ODT 50 µg control” |
| Placebo | “Placebo” |
| Dosing in Part A | “Single Dose” |
Dosing session monitoring and end-of-session checklist
No psychotherapy
Study outcomes
Rationale for using hamilton anxiety rating scale total score as the primary endpoint
Primary endpoint and sponsor rationale for Week 12
Registered primary outcome and HAM-A scoring
FDA guidance on a 12-week double-blind endpoint and blinded central raters
Minimal clinically important difference used in the phase 2b trial
Sponsor target product profile for the HAM-A difference
Key secondary multiplicity-controlled endpoints
Other registered secondary outcomes in Part A
Registered secondary outcomes in Part B
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized
Enrollment in the registry
| Field | Registry record |
|---|---|
| Enrollment (actual) | “245” |
| Planned maximum in the detailed description | “The study will enroll up to 375 participants aged 18 to 74 years” |
Participants analyzed in the ITT and safety populations
Planned enrollment: target of 200 participants after blinded sample size re-estimation, April 2026, superseded in August 2026
Planned enrollment: approximately 250 participants, January 2025, superseded in April 2026
Description of analysis sets
Primary analysis population and model
Multiplicity control of key secondary endpoints
Response and remission analyses
Subgroup analyses
Part B interim analysis populations
Results
Participant disposition
Part A disposition
| Group | Randomized | ITT population | Completed Part A |
|---|---|---|---|
| DT120 ODT 100 µg | “n=96” | “100% included in ITT population” | “90% completed Part A” |
| DT120 ODT 50 µg control | “n=52” | “100% included in ITT population” | “87% completed Part A” |
| Placebo ODT | “n=97” | “100% included in ITT population” | “90% completed Part A” |
Part B disposition at the interim analysis of August 11, 2026
| Part A group | Entered Part B | Through Week 28 | Through Week 36 | Through Week 52 |
|---|---|---|---|---|
| DT120 ODT 100 µg | “n=76” | “Through Week 28 (n=35)” | “Through Week 36 (n=24)” | “Through Week 52 (n=8)” |
| DT120 ODT 50 µg control | “n=42” | “Through Week 28 (n=19)” | “Through Week 36 (n=10)” | “Through Week 52 (n=3)” |
| Placebo ODT | “n=86” | “Through Week 28 (n=43)” | “Through Week 36 (n=35)” | “Through Week 52 (n=14)” |
Baseline characteristics
Demographics and baseline characteristics, ITT population
| Characteristic | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=52) | Placebo ODT (n=97) | Overall (n=245) |
|---|---|---|---|---|
| Mean age (years) | “39.8” | “40.4” | “42.3” | “40.9” |
| Sex (% female) | “62%” | “56%” | “62%” | “60%” |
| Race (% white) | “82%” | “85%” | “84%” | “83%” |
| Baseline HAM-A score, mean (SD) | “28.3 (5.5)” | “27.7 (4.8)” | “28.0 (5.6)” | “28.0 (5.4)” |
| Baseline CGI-S score, mean (SD) | “4.7 (0.5)” | “4.7 (0.6)” | “4.7 (0.6)” | “4.7 (0.6)” |
| Past use of any psychedelic, n (%) | “11 (12%)” | “8 (15%)” | “16 (17%)” | “35 (14%)” |
| Past use of LSD, n (%) | “4 (4%)” | “4 (8%)” | “8 (8%)” | “16 (7%)” |
Disease severity, treatment history, and comorbidity, ITT population
| Characteristic | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=52) | Placebo ODT (n=97) | Overall (n=245) |
|---|---|---|---|---|
| HAM-A moderate (<24), n (%) | “20 (21%)” | “9 (17%)” | “27 (28%)” | “56 (23%)” |
| HAM-A severe (≥24), n (%) | “76 (79%)” | “43 (83%)” | “70 (72%)” | “189 (77%)” |
| No past GAD treatments, n (%) | “29 (30%)” | “14 (27%)” | “17 (18%)” | “60 (25%)” |
| One past GAD treatment, n (%) | “20 (21%)” | “15 (29%)” | “22 (23%)” | “57 (23%)” |
| Two or more past GAD treatments, n (%) | “47 (49%)” | “23 (44%)” | “58 (60%)” | “128 (52%)” |
| Comorbid MDD, n (%) | “28 (29%)” | “17 (33%)” | “25 (26%)” | “70 (29%)” |
| MADRS score, mean (SD) | “13.3 (4.4)” | “13.4 (4.5)” | “13.5 (3.9)” | “13.4 (4.2)” |
| Years since diagnosis of GAD, mean (SD) | “6.9 (7.6)” | “9.4 (11.4)” | “9.9 (8.8)” | “8.6 (9.0)” |
| Years since onset of GAD symptoms, mean (SD) | “16.4 (12.6)” | “18.2 (15.5)” | “19.1 (13.4)” | “17.8 (13.6)” |
Characteristics at Part B entry
| Characteristic | DT120 ODT 100 µg (n=62) | DT120 ODT 50 µg control (n=33) | Placebo ODT (n=68) | Total (n=163) |
|---|---|---|---|---|
| Mean age (years) | “39.5” | “42.3” | “42.8” | “41.4” |
| Sex, female (%) | “62.9%” | “51.5%” | “58.8%” | “58.9%” |
| Race (% white) | “82.3%” | “87.9%” | “83.8%” | “84.0%” |
| HAM-A score at Part B entry | “18.3” | “21.6” | “23.3” | “21.1” |
| CGI-S score at Part B entry | “3.7” | “4.0” | “4.2” | “4.0” |
Efficacy results
Primary endpoint: change in HAM-A total score at Week 12
Primary, key secondary, and other secondary endpoints
| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
|---|---|---|---|
| HAM-A: LS mean change at Week 12 (primary) | “-9.8” | “-4.7” | “-5.1 (p<0.0001)” |
| CGI-S: LS mean change at Week 12 (key secondary) | “-1.0” | “-0.5” | “-0.6 (p<0.0001)” |
| HAM-A: LS mean change at Week 1 (key secondary) | “-9.8” | “-4.5” | “-5.3 (p<0.0001)” |
| CGI-S: LS mean change at Day 2 (key secondary) | “-1.1” | “-0.3” | “-0.8 (p<0.0001)” |
| HAM-A response rate (≥50%) at Week 12 | “32%” | “14%” | “18% (p<0.05)” |
| HAM-A remission rate (≤7) at Week 12 | “15%” | “4%” | “12% (p<0.05)” |
| HAM-A mild or better (<16) at Week 12 | “35%” | “17%” | “19% (p<0.01)” |
Odds ratios for response, remission, and mild or better at Week 12
| Outcome at Week 12 | Odds ratio, DT120 ODT 100 µg vs placebo |
|---|---|
| Response (HAM-A ≥ 50% improvement) | “Odds ratio: 2.9” |
| Remission (HAM-A ≤ 7) | “Odds ratio: 4.2” |
| Mild or better (HAM-A < 16) | “Odds ratio: 2.6” |
Treatment guess and functional unblinding
Subgroups analyzed for HAM-A change at Week 12
“Treatment Effect Maintained Across Key Subgroups” (opens the source at this quote in a new tab)
“Less than two (n=88)” (opens the source at this quote in a new tab)
“Two or more (n=105)” (opens the source at this quote in a new tab)
“Male (n=74)” (opens the source at this quote in a new tab)
“Female (n=119)” (opens the source at this quote in a new tab)
“<22 yrs (n=135)” (opens the source at this quote in a new tab)
“>22 yrs (n=58)” (opens the source at this quote in a new tab)
Part B interim analysis: response, remission, and mild or better through Week 28
Health-related quality of life and patient-reported outcomes
Patient-reported and functional outcomes registered for Part A
Results of patient-reported outcomes
No evidence found.
Safety results
Overview of adverse events in Part A
| Adverse event | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=51) | Placebo ODT (n=97) |
|---|---|---|---|
| Any TEAE | “91 (95%)” | “49 (96%)” | “61 (63%)” |
| Mild | “51 (53%)” | “29 (57%)” | “30 (31%)” |
| Moderate | “39 (41%)” | “19 (37%)” | “29 (30%)” |
| Severe | “1 (1%)” | “1 (2%)” | “2 (2%)” |
| Any study drug-related TEAE | “90 (94%)” | “47 (92%)” | “34 (35%)” |
| Any adverse event of special interest (AESI) | “84 (88%)” | “43 (84%)” | “31 (32%)” |
| Any SAE | “2 (2%)” | “1 (2%)” | “1 (1%)” |
| Any treatment-related SAE | “0” | “0” | “0” |
| Any TEAE leading to discontinuation | “0” | “0” | “0” |
| Any TEAE leading to death | “0” | “0” | “0” |
Tolerability summary and overall TEAE rates
TEAEs with incidence of 10% or more in the 100 µg arm, on and after dosing day
Mechanism-based adverse event categories
Suicidality
Time to meet end-of-session checklist criteria
Study limitations
Summary
Panorama randomized 245 participants 2:1:2 to a single dose of DT120 ODT 100 µg (96), DT120 ODT 50 µg (52), or placebo (97), and its primary analysis compares the 100 µg arm with placebo only. The 50 µg arm was not designed or powered for statistical comparisons, so the placebo-adjusted changes of -3.5 at Week 4 and -3.6 at Week 12 in that arm, and the dose-response statements built on them, carry no hypothesis test. The primary endpoint difference of -5.1 points (d=0.64) exceeds the 2.5-point minimal clinically important difference used in the phase 2b trial and the sponsor's 4-point target product profile; in the presentation's comparison of its trials, Panorama had a pooled endpoint standard deviation of 8.4. The study had no active comparator.
The 50 µg arm was included to mitigate functional unblinding, yet 91% (50 µg) and 95% (100 µg) of participants correctly guessed assignment to drug; no placebo-arm guess rate was reported. HAM-A ratings were made by central raters blinded to treatment assignment and visit number, and FDA guidance states that functional unblinding can lead to expectation bias. The sponsor states that the results support the conclusion that the dose response is not attributable to functional unblinding.
The results come from sponsor topline disclosures (an announcement, a slide presentation, and a Form 10-Q), the registry record lists no results posted, and one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results. These disclosures report no confidence intervals for the primary or key secondary endpoints. Response, remission, and mild-or-better rates (32% vs 14%, 15% vs 4%, 35% vs 17%) are other secondary endpoints outside the multiplicity-controlled key secondary endpoints. Subgroup analyses cover the 100 µg and placebo arms only, and the presentation states that small subgroups give unstable estimates. Patient-reported, functional, quality of life, and sexual functioning outcomes (PGI-S, WPAI-SHP, EQ-5D-5L, CSFQ-14) are registered but unreported.
Part B results come from an interim analysis as of August 11, 2026, based on partial data and subject to change, with open-label dosing and declining numbers of participants (87 at Week 12 and 27 at Week 28 in the response analysis); the 50 µg cohort was excluded for small numbers. The presentation reports two Part B denominators, 204 participants entering Part B (76, 42, and 86 by Part A group) and an extension population of 163 (62, 33, and 68), without stating how they differ. The sponsor states that Part B safety data are expected in a future presentation.
The enrolled population was 60% female and 83% white, aged 18 to 74 years, excluded a current major depressive episode, substance use disorder, and psychotic or bipolar disorder in the participant or a first-degree relative, and excluded systematic psychotherapy within 4 weeks before screening. The psychedelic use exclusion was later amended to any lifetime use; 35 participants (14%) reported past use of any psychedelic and 16 (7%) past use of LSD. Treatment history differed between arms: 60% of placebo participants and 49% of 100 µg participants had two or more past GAD treatments. Enrollment exceeded the target of 200 participants set after a blinded sample size re-estimation. The company reports approximately 32 study centers while the registry lists 36 locations. Participants were monitored for at least 8 hours on dosing day, and 94% of the 100 µg arm met end-of-session checklist criteria by hour 8. The methods report states that Definium Therapeutics funded the study and that all of its authors are company employees.
Functional unblinding in psychedelic trials
MMED008
Objective
Objective stated in the publication
“To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current phase 2b study assessed the dose response, efficacy, safety, and tolerability of a single treatment with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 vs placebo in participants with moderate to severe GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary, key secondary, and exploratory objectives in the protocol
Sponsor statement of the primary and key secondary objectives
Location and study date
Study dates in the registry
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2022-08-24” |
| Primary completion (actual) | “2023-10-06” |
| Study completion (actual) | “2023-11-27” |
| First posted | “2022-06-07” |
| Results first posted | “2025-03-20” |
Registered locations
Sites and conduct period reported in the publication
“was conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The last date of follow-up was November 27, 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was conducted at 22 outpatient psychiatric research sites across the US (eTable 2 in Supplement 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of clinical sites at completion of enrollment, September 2023, superseded in September 2025
Topline Week 12 results, March 2024
Journal publication, September 2025
Study design
Phase 2b randomized, double-blind, placebo-controlled, five-arm dose-finding design
“In this phase 2b, multicenter, double-blind, placebo-controlled trial, participants with GAD were randomized equally to receive a single (freebase equivalent) treatment dose with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 or placebo without stratification (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included 3 phases: (1) eligibility assessment (up to 35 days), (2) randomization (1 day), and (3) follow-up (12 weeks) (eFigure 1 in Supplement 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Protocol design and allocation ratio
Registry design fields
| Field | Registry record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Phase | “Phase 2” |
| Other study ID | “MMED008” |
Rationale for the dose levels and the placebo control
Blinded central rating of efficacy outcomes
“The HAM-A and the Montgomery-Åsberg Depression Rating Scale (MADRS) scores were assessed by independent central raters via telephone; the raters were blinded to the trial protocol, treatment allocation, and study visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To mitigate bias, the dosing session monitors were prohibited from conducting the efficacy assessments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single administration with no psychotherapeutic intervention
Eligibility criteria
Key eligibility criteria reported in the publication
“The eligibility criteria included age of 18 to 74 years, having a Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) primary diagnosis of GAD based on investigator assessment and confirmed by a Mini-International Neuropsychiatric Interview, and having moderate to severe anxiety (Hamilton Anxiety Rating Scale [HAM-A] score of ≥20) at both screening and at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The exclusion criteria included contraindicated medical or psychiatric conditions and inability or unwillingness to discontinue therapeutics with potential drug-drug interaction or anxiolytic effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disclosure or detection of the use of prohibited substances, including tetrahydrocannabinol, was cause for screening failure or discontinuation as was the use of any psychedelic within the past 2 years or more than 10 times within the past 10 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria in the protocol
Key exclusion criteria in the protocol: psychiatric history and substance use
Key exclusion criteria in the protocol: cardiovascular conditions
Suicide risk exclusion in the registry
Concurrent psychotherapy
“Participants undergoing psychotherapy at the time of screening could enroll but could not discontinue or modify session frequency during the study. Participants not receiving psychotherapy at screening could not initiate it during the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Treatment arms in the registry
| Arm | Registry record |
|---|---|
| Placebo | “Placebo Comparator: Arm 1- Placebo” |
| Lysergide 25 µg | “Experimental: Arm 2- 25 μg MM120” |
| Lysergide 50 µg | “Experimental: Arm 3- 50 μg MM120” |
| Lysergide 100 µg | “Experimental: Arm 4- 100 μg MM120” |
| Lysergide 200 µg | “Experimental: Arm 5- 200 μg MM120” |
| Intervention description | “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).” |
Number randomized to each arm
Capsule formulation and blinded dose preparation
Medication taper and washout before dosing
“Participants taking mood or anxiety medications at screening were required to discontinue them under the supervision of site physicians. Before the baseline visit, a medication washout period of 5 half-lives or greater was required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dosing session procedures and monitoring
“On the dosing day, participants received a single oral dose of MM120 or placebo. Each participant was continuously monitored on-site for safety and comfort by the same 2 dosing session monitors who conducted the participant’s educational session during the baseline visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participant dosing sessions were conducted individually in a private aesthetically pleasant room. The dosing sessions were not recorded or conducted in a group setting. Participants were offered standardized music and eyeshades and they could lie down, move freely around the room, read, write, or draw.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vital signs were measured throughout the dosing session and a physician was on-site in case comfort medications were needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Engaging in psychotherapy with the participant was explicitly prohibited by the trial protocol (Supplement 1). Starting 8 hours after the dose, participants were assessed hourly to characterize the resolution of the drug effects. Continuous monitoring was required for a minimum of 12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dosing session monitor qualifications
Study outcomes
Rationale for using hamilton anxiety rating scale Dose-Response at week 4 as the primary endpoint
Primary endpoint definition
“The primary outcome was a dose-response relationship assessed using the multiple comparison procedure modeling (MCP-Mod) method for change in HAM-A score at 4 weeks (score range, 0-56; higher scores indicate greater severity; ≤7 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and ≥24, severe).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The HAM-A score was assessed by independent central raters using the Structured Interview Guide for the Hamilton Anxiety Rating Scale.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered primary outcome and HAM-A items
Protocol rationale for the HAM-A as the efficacy measure
Protocol rationale for the Week 4 time point, the Week 8 key secondary endpoint, and the HAM-A entry threshold
Rationale for the MCP-Mod analysis and the minimal clinically important difference
“The primary outcome and the key secondary outcome were evaluated using the MCP-Mod approach at the 5% significance level, which integrates hypothesis testing with dose-response modeling and is endorsed by regulatory agencies for dose selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A placebo-adjusted difference of 2.5 points for change in HAM-A score was used as the threshold (minimal clinically important difference of 2.5 points) for determining the minimally efficacious dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary, secondary, and exploratory endpoints
“The key secondary outcome was a dose-response relationship” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“assessed using the MCP-Mod method for change in HAM-A score at 8 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rates of response (≥50% change [reduction] in HAM-A score from baseline) and remission (HAM-A score ≤7) were also explored.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effects of MM120 on functional disability, quality of life, and sexual function were assessed throughout the trial using the Sheehan Disability Scale, the EuroQol 5-dimension 5-level questionnaire, the Pittsburgh Sleep Quality Index, and the Arizona Sexual Experiences Questionnaire.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blinding of the participants and raters regarding treatment allocation (active drug, placebo, or indiscernible) was assessed using a 5-point questionnaire (range, 1 [positive they received drug] to 5 [positive they received placebo]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety endpoints
“Safety and tolerability were evaluated through adverse event (AE) monitoring, physical and neuropsychiatric examinations, vital signs, electrocardiographic monitoring, and laboratory tests. Suicidal ideation and behavior were assessed at each visit using the Columbia–Suicide Severity Rating Scale (C-SSRS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Target sample size in protocol version 6.0, July 2023
Planned enrollment at first participant dosing, August 2022
Participants randomized and analyzed
Description of analysis sets
Analysis sets used for efficacy and safety
“Efficacy was analyzed in the full analysis set, which was composed of all randomized participants with a HAM-A measurement at baseline and at least 1 HAM-A measurement after baseline. Safety was evaluated in all participants who were randomized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analysis sets defined in the statistical analysis plan
MCP-Mod testing procedure and dose-response models
“Six candidate dose-response models were prespecified to represent a range of plausible dose-response shapes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“assessed under strict type I error control at the 5% level using a hierarchical gatekeeping testing procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated dose-response curve was derived using an Akaike information criterion–weighted average of the top 3 dose-response models.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Handling of missing data and intercurrent events
“Missing primary end point data were imputed using multiple imputations with 20 iterations. Observations missing due to prohibited medication use were assumed to be missing not at random and imputed using placebo-based imputation. All other missing observations were imputed under the assumption of missing at random.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary analyses without imputation or multiplicity adjustment
“Change in HAM-A score from baseline was analyzed using an analysis of covariance model adjusted for the baseline values and treatment group without imputation (observed cases only).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other secondary efficacy outcomes were analyzed using 2-sample t tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect size calculation
“Cohen d was calculated as the bias-corrected least-squares estimate of the treatment difference in changes from baseline to a given time point (from an analysis of covariance model), divided by the pooled SD of observed values at the same time point from a given active dose group and the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Enrollment period and randomization in the publication
“Between August 24, 2022, and August 30, 2023, a total of 554 participants were screened; of these, 198 were randomized and received a single (freebase equivalent) treatment dose with 25 µg (n = 39), 50 µg (n = 40), 100 µg (n = 40), or 200 µg (n = 40) of MM120 or placebo (n = 39) (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Completion through Week 4 in the topline announcement
Baseline characteristics
Demographics of the full analysis set
“Of the 198 participants randomized, 194 were included in the full analysis set (mean age, 41.3 [SD, 13.6] years; 56.7% were female; and 3.6% were Asian, 7.7% were Black or African American, and 83.0% were White) (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean HAM-A scores at baseline were equivalent across groups (score range, 29.3-31.0).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline demographics and disease characteristics by arm
Prior treatment and medication taper at screening
“At screening, 84% of participants required tapering prohibited medications, 16% were treatment-naive, and 18% were receiving psychotherapy at the time of enrollment; psychotherapy was allowed to continue through the trial. Of the participants who required tapering prohibited medications, 43% were taking serotonin reuptake inhibitors, 34% were taking benzodiazepines, and 19% were taking antipsychotics or antiepileptics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline severity described by the sponsor
Efficacy results
Primary endpoint: MCP-Mod dose-response for HAM-A change at Week 4
“A significant MM120 dose-response relationship was demonstrated at both week 4 (primary outcome) and week 8 (key secondary outcome) based on changes from baseline in HAM-A score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 4, the adjusted critical value was 2.032 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 3.294, 3.149, 3.133, 1.448, 3.471, and 2.971, respectively. Therefore, 5 of the 6 models, including the linear, Emax, and multiple sigmoid Emax variants, met the significance threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the primary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 4 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −5.0 points [95% CI, −9.6 to −0.4 points] with 100 µg of MM120 and −6.0 points [95% CI, −9.8 to −2.0 points] with 200 µg of MM120) but the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −1.2 points [95% CI, −6.0 to 3.5 points] with 25 µg of MM120 and −1.8 points [95% CI, −7.6 to 4.0 points] with 50 µg of MM120)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint: model-based estimates at Week 4 by arm
| Arm | Least-squares mean change (95% CI) | Least-squares mean difference vs placebo (95% CI) |
|---|---|---|
| Placebo | “−14.2 (−17.8 to −10.6)”View highlighted excerpt for this quote | Not applicable |
| Lysergide 25 µg | “−15.4 (−17.6 to −13.1)”View highlighted excerpt for this quote | “−1.2 (−6.0 to 3.5)”View highlighted excerpt for this quote |
| Lysergide 50 µg | “−16.0 (−19.4 to −12.7)”View highlighted excerpt for this quote | “−1.8 (−7.6 to 4.0)”View highlighted excerpt for this quote |
| Lysergide 100 µg | “−19.2 (−21.7 to −16.7)”View highlighted excerpt for this quote | “−5.0 (−9.6 to −0.4)”View highlighted excerpt for this quote |
| Lysergide 200 µg | “−20.1 (−22.9 to −17.3)”View highlighted excerpt for this quote | “−6.0 (−9.8 to −2.0)”View highlighted excerpt for this quote |
Primary endpoint as posted on the registry
| Arm | Mean change from baseline to Week 4, model averaging (95% CI) | Mean difference from placebo (95% CI) |
|---|---|---|
| Placebo | “-14.23 (-17.83 to -10.63)” | Not applicable |
| Lysergide 25 µg | “-15.35 (-17.62 to -13.09)” | “-1.24 (-6.01 to 3.53)” |
| Lysergide 50 µg | “-16.05 (-19.40 to -12.71)” | “-1.82 (-7.65 to 4.00)” |
| Lysergide 100 µg | “-19.22 (-21.73 to -16.70)” | “-5.02 (-9.60 to -0.44)” |
| Lysergide 200 µg | “-20.09 (-22.87 to -17.31)” | “-5.95 (-9.84 to -2.06)” |
Minimally efficacious dose
“These selected models at each time point were incorporated into an Akaike information criterion–weighted model-averaging procedure to estimate the dose-response curve and calculate the minimally efficacious dose, which was found to be between 56.7 µg and 85.1 µg (eFigure 2 in Supplement 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint: MCP-Mod dose-response for HAM-A change at Week 8
“At week 8, the adjusted critical value was 2.041 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 2.099, 2.922, 2.938, 2.254, 2.690, and 2.778, respectively. Therefore, all 6 models met the significance threshold, with the linear, Emax, and sigmoid Emax models selected as the best fitting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the key secondary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 8 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −2.9 points [95% CI, −5.4 to −0.5 points] with 100 µg of MM120 and −5.4 points [95% CI, −9.5 to −1.4 points] with 200 µg of MM120) but” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −0.8 points [95% CI, −1.7 to 0.2 points] with 25 µg of MM120 and −1.4 points [95% CI, −3.1 to 0.2 points] with 50 µg of MM120)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 4 HAM-A difference at 100 µg: observed-case ANCOVA secondary analysis in the publication
“For the secondary outcome at week 4, the 100-µg and the 200-µg dose groups significantly reduced HAM-A score vs placebo (the least-squares mean difference was −7.6 points [95% CI, −11.8 to −3.4 points; P < .001; Cohen d = 0.88] with 100 µg of MM120 and was −5.5 points [95% CI, −9.7 to −1.3 points; P = .01; Cohen d = 0.64] with 200 µg of MM120)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 4, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −3.4 points (95% CI, −7.7 to 0.9 points; P = .12) with 25 µg of MM120 and the reduction was −0.9 points (95% CI, −5.2 to 3.3 points; P = .66) with 50 µg of MM120.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 4 HAM-A difference at 100 µg: company topline announcement, December 2023
Week 4 HAM-A difference at 100 µg: company publication announcement, September 2025
HAM-A change from baseline by week: observed-case ANCOVA differences from placebo
HAM-A change at Weeks 8 and 12
“For the secondary outcome at week 8, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −4.3 points (95% CI, −8.9 to 0.3 points; P = .06; Cohen d = 0.48) for 100 µg of MM120 and the reduction was −5.5 points (95% CI, −10.2 to −0.8 points; P = .02; Cohen d = 0.60) for 200 µg of MM120. At week 12, compared with placebo, the reduction in HAM-A score was shown with a least-squares mean difference of −7.7 points (95% CI, −12.6 to −2.8 points; P = .003; Cohen d = 0.81) with 100 µg of MM120 and the reduction was −7.4 points (95% CI, −12.4 to −2.4 points; P = .004; Cohen d = 0.77) with 200 µg of MM120.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HAM-A change at Week 12: company topline announcement, March 2024
HAM-A response and remission at Week 12
“The secondary outcome of HAM-A response (defined by a 50% reduction in total score) at week 12 was achieved by 65.0% of participants in the 100-µg dose group and by 62.5% in the 200-µg dose group compared with 30.8% of participants in the placebo group and the remission rates at week 12 were 47.5%, 45.0%, and 20.5%, respectively (eFigure 4 and eTable 3 in Supplement 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HAM-A response and remission at Weeks 4 and 12 by arm
| Outcome | Placebo (n=39) | 25 μg (n=39) | 50 μg (n=36) | 100 μg (n=40) | 200 μg (n=40) |
|---|---|---|---|---|---|
| Response, Week 4, n (%) | “12 (30.8%)” | “20 (51.3%)” | “21 (58.3%)” | “31 (77.5%)” | “31 (77.5%)” |
| Response, Week 12, n (%) | “12 (30.8%)” | “17 (43.6%)” | “20 (55.6%)” | “26 (65.0%)” | “25 (62.5%)” |
| Remission, Week 4, n (%) | “7 (17.9%)” | “11 (28.2%)” | “9 (25.0%)” | “20 (50.0%)” | “14 (35.0%)” |
| Remission, Week 12, n (%) | “8 (20.5%)” | “11 (28.2%)” | “12 (33.3%)” | “19 (47.5%)” | “18 (45.0%)” |
HAM-A response and remission at Week 4: company topline announcement, December 2023
Clinician-rated illness severity (CGI-S)
“The statistically significant improvements in illness severity (measured using the CGI-S score) were observed on day 2 and at weeks 2 through 12 in the 100-µg and 200-µg dose groups, but not in the 25-µg or 50-µg dose groups or in the placebo group. At week 1, all MM120 dose groups demonstrated significant improvements, but the placebo group did not” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CGI-S mean difference from placebo on Day 2 and at Week 12
CGI-S change described by the sponsor
Depressive symptoms (MADRS)
MADRS mean difference from placebo at Weeks 4 and 12
MADRS change described by the sponsor
Functional unblinding and placebo response
“All doses of MM120 produced transient perceptual, cognitive, and emotional effects leading to participant unblinding.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“despite approximately 85% of participants correctly identifying assignment to active treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, even though more than 65% of participants accurately identified their assignment as placebo recipients, a robust placebo effect was observed that was comparable with or exceeded trials of anxiolytics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup analyses
Health-related quality of life and patient-reported outcomes
Functional, quality-of-life, sleep, and sexual function outcomes reported in the supplement
“Additional secondary outcomes, including changes in scores for the Sheehan Disability Scale, the EuroQol 5-dimension 5-level questionnaire, the Pittsburgh Sleep Quality Index, and the Arizona Sexual Experiences Questionnaire appear in eTable 6 in Supplement 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the secondary outcomes focused on functional disability, the changes from baseline were analyzed descriptively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sheehan Disability Scale total score at Week 12
| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
|---|---|---|---|
| Placebo | “-8.2 (8.61)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-10.8 (7.72)” | “-2.59” | “(-7.10 to 1.91)” |
| Lysergide 50 μg | “-9.0 (9.17)” | “-0.83” | “(-5.70 to 4.03)” |
| Lysergide 100 μg | “-15.1 (5.78)” | “-6.86” | “(-10.89 to -2.83)” |
| Lysergide 200 μg | “-13.1 (7.51)” | “-4.93” | “(-9.33 to -0.53)” |
EQ-5D-5L visual analog scale at Week 12
| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
|---|---|---|---|
| Placebo | “11.7 (18.24)” | Not applicable | Not applicable |
| Lysergide 25 μg | “17.0 (18.53)” | “5.31” | “(-4.65 to 15.27)” |
| Lysergide 50 μg | “13.2 (13.97)” | “1.55” | “(-7.34 to 10.45)” |
| Lysergide 100 μg | “17.7 (13.68)” | “6.04” | “(-2.61 to 14.70)” |
| Lysergide 200 μg | “17.3 (19.40)” | “5.64” | “(-4.37 to 15.65)” |
Pittsburgh Sleep Quality Index global score at Week 12
| Arm | Observed mean (SD) change from baseline | Difference from placebo in mean change | 95% CI of the difference |
|---|---|---|---|
| Placebo | “-4.3 (4.22)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-5.5 (4.01)” | “-1.25” | “(-3.48 to 0.99)” |
| Lysergide 50 μg | “-4.8 (3.88)” | “-0.55” | “(-2.77 to 1.67)” |
| Lysergide 100 μg | “-5.9 (4.13)” | “-1.64” | “(-3.84 to 0.56)” |
| Lysergide 200 μg | “-4.9 (4.11)” | “-0.60” | “(-2.83 to 1.62)” |
Patient Global Impression of Severity and of Change at Week 12
| Arm | PGI-S difference from placebo in mean change | PGI-S 95% CI | PGI-C observed mean (SD) | PGI-C difference from placebo | PGI-C 95% CI |
|---|---|---|---|---|---|
| Placebo | Not applicable | Not applicable | “2.2 (0.98)” | Not applicable | Not applicable |
| Lysergide 25 μg | “-0.34” | “(-0.91 to 0.24)” | “1.8 (0.71)” | “-0.36” | “(-0.83 to 0.10)” |
| Lysergide 50 μg | “-0.30” | “(-0.94 to 0.34)” | “1.8 (1.00)” | “-0.36” | “(-0.90 to 0.17)” |
| Lysergide 100 μg | “-0.47” | “(-1.05 to 0.11)” | “1.5 (0.67)” | “-0.71” | “(-1.16 to -0.25)” |
| Lysergide 200 μg | “-0.37” | “(-1.01 to 0.26)” | “1.7 (0.98)” | “-0.51” | “(-1.04 to 0.01)” |
Sexual dysfunction (ASEX) at Week 12
| Arm | Females with sexual dysfunction, n (%) | Males with sexual dysfunction, n (%) |
|---|---|---|
| Placebo | “6 (33.3)” | “1 (12.5)” |
| Lysergide 25 μg | “4 (25.0)” | “3 (23.1)” |
| Lysergide 50 μg | “10 (66.7)” | “1 (7.1)” |
| Lysergide 100 μg | “6 (46.2)” | “2 (10.0)” |
| Lysergide 200 μg | “7 (33.3)” | “0 (0)” |
Safety results
Overview of adverse events
“The rate for 1 or more treatment-emergent adverse events (TEAEs) was 76.9% in the 25 µg of MM120 group, was 90.0% in the 50-µg group, was 97.5% in the 100-µg group, and was 100% in the 200-µg group vs 56.4% in the placebo group (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of all the AEs, 98.5% occurred on the dosing day and most resolved by the end of the dosing session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in the safety population by arm
Most frequent dosing-day adverse events at 100 µg and 200 µg
“On the dosing days, the most frequent AEs reported in the 100-µg and 200-µg dose groups were visual perceptual changes (illusion, pseudo-hallucination, hallucination) in 92.5% and 100% of participants, respectively, nausea in 40.0% and 60.0%, headache in 35.0% and 27.5%, and euphoric mood in 27.5% and 15.0%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Most common adverse events as stated in the company publication announcement, September 2025
Serious adverse events
Suicidal ideation and behavior
“No participants engaged in self-injurious or suicidal behavior, which was assessed using the C-SSRS and AE reporting. There were no reports of suicidal ideation with intent or a plan during the sessions or throughout the trial. Participants with a history of suicidal ideation showed no increase in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicidal ideation reported as an adverse event in the registry
| Arm | Affected / at risk (%) |
|---|---|
| Placebo | “1/39 (2.56%)” |
| Lysergide 25 μg | “1/39 (2.56%)” |
| Lysergide 50 μg | “2/40 (5.00%)” |
| Lysergide 100 μg | “2/40 (5.00%)” |
| Lysergide 200 μg | “0/40 (0.00%)” |
Resolution of acute effects and time to meeting session-end criteria
“Resolution of acute effects from MM120 was observed in more than 97% of participants at all MM120 doses by 12 hours after the dose was administered (eFigure 6 in Supplement 3). In the 100-µg dose group, 45.0% of participants met criteria to safely end the session at 8 hours, 70.0% at 9 hours, 87.5% at 10 hours, 90.0% at 11 hours, and 97.5% at 12 hours. All participants remained at the study site until 12 hours after the dosing session regardless of meeting criteria to safely end the session per the trial protocol (Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor summary of tolerability
Pooled safety analysis including the phase 2b 100 µg and 200 µg arms
Study limitations
Summary
The trial randomized 198 participants at 22 outpatient sites in the United States to a single dose of lysergide capsules (25, 50, 100, or 200 µg) or placebo, with 12 weeks of follow-up and no study-related psychotherapy. The phase 3 trials use an orally disintegrating tablet, so the phase 2b results were obtained with a different formulation.
- Primary analysis and reported effect size: the prespecified MCP-Mod primary analysis with multiple imputation gave a least-squares mean difference from placebo at Week 4 of −5.0 points (95% CI, −9.6 to −0.4) for 100 µg. The 7.6-point difference (Cohen d = 0.88) that company announcements report for Week 4 is the publication's secondary outcome at Week 4. The publication states that change in HAM-A score from baseline was analyzed by analysis of covariance without imputation (observed cases only), while missing primary end point data were imputed by multiple imputation; the registry results state that missing data were not imputed for non-key secondary efficacy endpoints.
- Multiplicity: only the primary and key secondary outcomes were controlled for type I error; other hypothesis tests, including the Week 12 difference of −7.7 points and the response and remission rates, were not adjusted for multiple comparisons.
- Functional unblinding: the authors state that the perceptible drug effects may have led to unblinding, and approximately 85% of participants correctly identified assignment to active treatment. Efficacy was rated by central raters blinded to protocol, treatment allocation, and visit.
- Dosing session monitors: two monitors were present throughout each session, and the authors state that confounding effects of interpersonal interactions remain a possibility.
- Missing data: 147 of 198 randomized participants (74.2%) completed the study, and the authors describe the dropout rate as slightly higher than in studies of similar molecules.
- Population: participants were physically healthy with limited psychiatric comorbidities, discontinued anxiolytic and antidepressant medications before dosing, and 83.0% were White; 18% received psychotherapy outside the trial.
- Sample size: 36 to 40 participants per arm in the full analysis set; analyses by sex and other characteristics were not conducted because of insufficient statistical power.
- Adverse event figures for visual perceptual changes, nausea, and headache in the company publication announcement differ from those in the journal article (for example, nausea at 100 µg 42.5% versus 40.0%).
Limitations stated in the publication
“Despite dosing session monitors explicitly not providing a systematic psychotherapeutic intervention, confounding effects of interpersonal interactions remain a possibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, the perceptible drug effects of MM120 may have led to unblinding, which could have influenced the outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, the primary outcome and key secondary outcome were strictly controlled for type I error, but the other hypothesis tests were not adjusted for multiple comparisons. Fourth, the dropout rate, though similar across groups, was slightly higher than in studies of similar molecules.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This higher dropout rate may be due to the 12-week duration of the trial, the required discontinuation of GAD medications, and the absence of an extension phase with opportunities for open-label treatment. Fifth, the participants were physically healthy with limited psychiatric comorbidities, potentially enhancing the tolerability of transient AEs. Sixth, the process of tapering participants from prohibited psychoactive medications ensured MM120 was assessed as a monotherapy; however, we did not address concomitant use of other pharmacotherapies. Seventh, some participants engaged in psychotherapy outside the trial, which may have affected dosing-day experiences and efficacy outcomes, though this was the case for only 18% of participants. Eighth, the study population was inclusive in terms of sex and age but was racially and ethnically less diverse than the general population of people with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations and caveats in the registry results
LSD-assist
Objective
Registered objective
Published aim of the primary analysis
“This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association with a life-threatening illness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aim of the long-term follow-up
“We investigated the long-term safety and efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with anxiety with or without life-threatening illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We hypothesised effects would not be sustained up to the 12-month follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role in the development of DT120 (MM-120)
Location and study date
Study identifiers, dates, and status
| Item | Registry record |
|---|---|
| Brief title with acronym | “LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders (LSD-assist)” |
| Other study ID | “BASEC 2016-00992” |
| Phase | “Phase 2” |
| Study start (actual) | “2017-06-23” |
| Primary completion (actual) | “2021-12-15” |
| Study completion (actual) | “2021-12-15” |
| First posted | “2017-05-15” |
| Last update posted | “2021-12-22” |
| Results | “No Results Posted” |
Sites: two centers in Switzerland
“This study has 2 locations” (opens the source at this quote in a new tab)
“Sponsor University Hospital, Basel, Switzerland” (opens the source at this quote in a new tab)
“The study was an investigator-initiated, two-centre trial, with one study centre at the University Hospital Basel, Switzerland, and the other study centre at the Clinic Dr Peter Gasser, Solothurn, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enrollment period, last visit, and follow-up completion
“Enrolment began on 23 June 2017 and finished on 1 February 2021. The trial ended as planned, with the last patient visit on 15 December 2021. The assessment of follow-up questionnaires was completed by January 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First presentation of results, May 2022
Study design
Official title and registered design
| Design element | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Quadruple” |
Two-center, two-period, random-order crossover design
“The study is an investigator-initiated 2-center trial that used a double-blind, placebo-controlled, 2-period, random-order, crossover design with 2 sessions with either oral LSD (200 μg) or placebo per period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment periods, session spacing, and visit schedule
“The order of administration was random and counterbalanced.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After study inclusion, the participants were randomly assigned to LSD or placebo in the first treatment period and vice versa in the second treatment period by order of enrolment and group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As previously reported in detail, the study included a screening visit and two 24-week treatment periods per participant. Each treatment period consisted of two treatment sessions and five study visits. Treatment sessions were separated by 6 weeks (±2 weeks). Study visits were conducted at baseline, between treatment sessions, and 2, 8 and 16 weeks after the second treatment session. The last visit in the second period also served as the end-of-study visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Planned long-term follow-up by mailed questionnaire
“Follow-up questionnaires were sent by mail to all participants (including dropouts) 12 months after the end-of-study visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For those who received LSD in the first period, the follow-up was assessed 94 weeks after the last LSD treatment. For those who received placebo in the first period, the follow-up was assessed 68 weeks after the last LSD treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The follow-up was conducted 12 months after the end-of-study visit by post to investigate the same outcome measures as during the study, in which participants completed questionnaires about long-lasting effects and answered questions about adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Funding, ethics approval, and licensing of the data to the developer of DT120
“The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines in Good Clinical Practice and approved by the Ethics Committee of Northwest Switzerland (EKNZ), Swiss Federal Office for Public Health, and Swissmedic” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was funded by the University Hospital Basel and Swiss Medical Society for Psycholytic Therapy (SAePT). The funders of the study had no role in the study design, data collection, data analysis, data interpretation or writing the report. M.E.L. and P.G. are consultants for Mind Medicine, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Knowhow and data associated with this work and owned by the University Hospital Basel were licensed by Mind Medicine, Inc., which had no role in financing, planning or conducting the present study or the present publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria
Exclusion criteria
Anxiety disorder diagnoses eligible, including generalized anxiety disorder
“The goal was to include people with anxiety disorders or significant anxiety that was associated with LTI. LTI was defined as any severe somatic disease, such as a diagnosis of cancer or another advanced-stage potentially fatal illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“criteria for an anxiety disorder, including generalised anxiety disorder, social phobia and panic disorder, as indicated by the Structured Clinical Interview for the DSM-IV (SCID-IV), or have a score ≥40 on the state or trait STAI at study inclusion. Participants without LTI had to meet DSM-IV criteria for at least one anxiety disorder. Thus, in people without LTI, elevated STAI scores were not sufficient for inclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recruitment
“Participants were recruited through an advertisement that was placed on website homepages of the University Hospital Basel and Swiss Medical Society for Psycholytic Therapy (SAePT) trial registries, or by word of mouth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Registered interventions
Study drug and placebo as described in the follow-up publication
“LSD free base (>99% purity; Lipomed AG, Arlesheim, Switzerland) was administered as an oral solution in units that contained 100 μg LSD in 1 mL of 96% ethanol. Inactive placebo consisted of identical units that were filled with ethanol only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomisation and production were performed according to good manufacturing practice (GMP) by a licensed GMP facility (Apotheke Dr Hysek, Biel, Switzerland).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Session setting, duration, and therapist
“After successful screening, each person was assigned for the entire duration of the study to one investigator/therapist who conducted all treatment sessions and study visits. Treatment sessions lasted approximately 12 h, and study visits lasted approximately 1 h. Study visits consisted of talk therapy, followed by an assessment of adverse events, changes in general medication and administration of the questionnaires.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment sessions were conducted in a calm hospital room (University Hospital Basel) or calm practice room (Clinic Dr Peter Gasser). Only one participant and one investigator/therapist were present during the treatment sessions (exceptions of more than one therapist being present were made upon request by the therapist or participant).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Background treatment: LSD given as an add-on
“However, most people had already received some therapy (e.g. anxiolytics, antidepressants or talking psychotherapy) when they entered the trial, and antidepressant treatment was only tapered off for LSD/placebo sessions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSD therapy therefore served as an add-on for those who had already received treatment at trial inclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Additional psychedelic sessions after the trial
“Six individuals from the original study continued psychedelic therapy (LSD, 3,4-methylenedioxymethamphetamine (MDMA) or psilocybin) within the Swiss limited-use programme and underwent one to four additional psychedelic sessions (all LSD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using State-Trait anxiety inventory global score as the primary endpoint
Registered primary and secondary outcomes
| Outcome | Quoted registry text |
|---|---|
| Primary | “Reduction in anxiety assessed by questionnaires (STAI) 16 weeks after LSD compared with placebo” |
| Primary time frame | “16 weeks post-intervention” |
| Secondary: depression | “Reduction in depression will be assessed by questionnaires (HDRS, BDI) 2, 8 and 16 weeks after LSD compared with placebo” |
| Secondary: anxiety at earlier visits | “Reduction in anxiety will be assessed by questionnaire (STAI) 2 and 8 weeks after LSD compared with placebo” |
| Secondary: psychopathology | “Reduction of psychopathological symptoms will be assessed by questionnaire (SCL-90) 2, 8, and 16 weeks after LSD compared with placebo” |
| Secondary: sustained response | “Follow-up using different questionnaires to compare (within-subject) the 52-week response with Responses from baseline and 16-weeks.” |
Primary endpoint as published: STAI-Global score at 16 weeks
“The primary end point was anxiety symptoms 16 weeks after the last treatment session, assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients. Further outcome measures included ratings for depression symptoms (Beck Depression Inventory and Hamilton Depression Rating Scale, 21-item version) and ratings for acute subjective drug effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Purpose of the STAI global score as stated by the sponsor
Response and remission definitions
“The clinical response was defined as a STAI-G reduction ≥ 30%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remission was defined as score <80 for the STAI-G.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remission was defined as score <10 for the BDI; only patients with a score of ≥10 at screening were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcome measures of the long-term follow-up
“The primary outcome measure in the present study was defined the STAI-G (with the primary end-point 16 weeks after the last treatment session, as reported previously).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary outcomes that were assessed during the study and at the follow-up were scores on the STAI-State (STAI-S), STAI-Trait (STAI-T), BDI and SCL-90-R.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At follow-up, in addition to the therapeutic outcome questionnaires, a questionnaire about persisting effects of psychedelics was administered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Personality traits at screening and the 1-year follow-up were assessed using the 60-item NEO - Five-Factor Inventory (NEO-FFI)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled: 46 participants
Analyzed in the primary analysis: 42 participants
Analyzed at long-term follow-up
“Follow-up questionnaires were returned by 35 individuals (15 in the group with LTI and 20 without LTI). People who had at least two LSD sessions and one outcome measure were included in the analysis. One person did not complete the STAI questionnaires, resulting in a total of 33 people for all STAI measures and 34 people for all other measures. A total of 39 participants (20 in the LSD-first group and 19 in the placebo-first group) were eligible for the change-from-baseline analysis per treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Primary analysis restricted to the first period because of carryover
Follow-up analysis set and statistical model
“People who had at least two LSD sessions and one outcome measure were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcomes were analysed using Linear Mixed Effects models, employing the lme4 and lmer test packages in R. Time points were used as the fixed factor, and participants were used as the random factor. For therapeutic outcomes but not personality traits, baseline values of the periods were considered covariates (change from baseline values for the respective period).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tukey's post hoc pairwise comparisons of least square means across time points were performed to elucidate significant differences between baseline and follow-up. These analyses were planned and hypothesised a priori in the protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory associations between the acute response to LSD and main follow-up outcome measures were assessed using Pearson's correlations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The criterion for significance was P < 0.05.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Enrolled and analyzed in the primary analysis
Participants contributing data at long-term follow-up
“Detailed data on dropouts during the study were previously reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Follow-up questionnaires were returned by 35 individuals (15 in the group with LTI and 20 without LTI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We received written feedback from 18 participants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Duration of anxiety and prior treatment
“On average, people were diagnosed with anxiety 10 ± 9 years (mean ± s.d.) prior to study inclusion (range: 0–39 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many of the participants in the present trial had a long history of treatment attempts/failures and were to some degree non-responsive chronic cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imbalance in symptom ratings between sequence groups
Personality trait openness at study inclusion
Efficacy results
Primary endpoint: STAI-Global change at 16 weeks (between-subjects analysis)
“LSD treatment resulted in significant reductions of State-Trait Anxiety Inventory-Global scores up to 16 weeks after treatment (least-square mean [standard error] change from baseline difference = -16.2 [5.8], 95% CI, -27.8 to -4.5, d = -1.18, p = .007).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Depression: HAM-D-21 and BDI
“Similar effects were observed for ratings of comorbid depression on the Hamilton Depression Rating Scale, 21-item version (-7.0 [1.9], 95% CI, -10.8 to -3.2, d = -1.1, p = .0004) and the Beck Depression Inventory (-6.1 [2.6], 95% CI, -11.4 to -0.9, d = -0.72, p = .02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
STAI-G response and time course reported at the oral presentation
Follow-up at 12 months after the end-of-study visit: STAI-G change from baseline
“Participants reported a sustained reduction of STAI-G scores compared with baseline (least square means (95% CI) = −21.6 (−32.7, −10.4), d = 1.04, P < 0.001, for those who received LSD in the first period (94 weeks after the last LSD treatment) and −16.5 (−26.2, −6.8), d = 1.02, P < 0.05, for those who received LSD in the second period (68 weeks after the last LSD treatment)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The LSD-first group improved significantly on the STAI-G compared with the primary end-point (16 weeks after last drug administration) at follow-up. The least square mean (95% CI) change was −9.7 (−15.5, −4.0), while the placebo-first group showed no further improvement: 1.2 (−4.2, 6.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up at 12 months: depression
“Similar effects were observed for comorbid depression with change from baseline BDI scores of −8.1 (−13.2, −3.1), d = 0.71, P < 0.01, and −8.9 (−12.9, −4.9), d = 1.21, P < 0.01, for the LSD-first and placebo-first groups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up at 12 months: remission and response
“At follow-up, a total of 11 participants (33%) were in remission with regard to anxiety symptoms, and a total of 17 participants (49%) were in remission with regard to depression symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroups: life-threatening illness, further psychedelic therapy, and generalized anxiety disorder
“Post hoc tests revealed no significant differences between people with and without LTI (P = 0.45 for the LSD-first group and P = 0.41 for the placebo-first group), people whose therapy was continued within the Swiss limited-use programme (P = 0.89 for the LSD-first group and P = 0.66 for the placebo-first group) and people with a formal diagnosis of generalised anxiety disorder (GAD; P = 0.35 for the LSD-first group and P = 0.65 for the placebo-first group).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present study included participants with a range of anxiety diagnoses that were included based on their symptom severity; this approach is supported by the findings that we found no difference in response between the groups (LTI versus non-LTI) and diagnosis (GAD versus non-GAD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Persisting Effects Questionnaire at follow-up
“On the PEQ, high ratings of positive attitudes about life and/or self, positive mood changes, altruistic/positive social effects and positive behavioural changes were reported (all >47% of the total maximum score), whereas ratings of the negative counterparts remained low (all <10% of the total maximum score).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, people rated the experience as ‘among the ten most personally meaningful experiences in life’, as ‘very much’ spiritually meaningful and as having positively influenced their sense of well-being or life satisfaction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
General psychiatric symptoms (SCL-90-R)
Written participant feedback at follow-up
“We received written feedback from 18 participants, which included the following topics: therapeutic potential of LSD (14 participants; 13 positive, one negative), setting and atmosphere (five participants; three positive, two negative), guide/therapist interaction (two participants; one positive, one negative), dose-related feedback (two participants; both negative (one participant reported the dose was too high, and one participant reported the dose was too low)), post-session effects (two participants; one positive, one negative) and comparison between dosing days (one participant; negative).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Acute untoward effects and treatment-related serious adverse event
Serious adverse event description and suicidality
Long-term safety: flashbacks and hallucinogen persisting perception disorder
“Additionally, the follow-up questionnaire included questions about adverse effects, including flashbacks and hallucinogen persisting perception disorder (HPPD; see Supplemental Information for detailed questions)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No additional adverse events were reported in the follow-up period, and no additional clinically relevant flashback phenomena or HPPD occurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSD did not induce any long-term adverse events, such as flashbacks or HPPD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lasting negative effects were minimal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
NCT03153579 was an investigator-initiated phase 2 crossover trial at two centers in Switzerland (University Hospital Basel and a private practice in Solothurn), funded by University Hospital Basel and the Swiss Medical Society for Psycholytic Therapy. The registered summary planned 40 participants; 46 were enrolled, and 42 were included in the primary analysis. Because of carryover effects, the primary results are a between-subjects comparison of the first period, in which a STAI-G response (reduction of 30% or more) was reported for 13 of 20 participants (65%) receiving LSD and 2 of 22 (9%) receiving placebo. The response figures come from the May 2022 company announcement of an oral presentation; the primary publication reports the least-squares mean difference of -16.2 points (95% CI, -27.8 to -4.5) at 16 weeks.
The population combined participants with an anxiety disorder and participants with anxiety associated with a life-threatening illness, for whom a STAI score of 40 or more could substitute for a DSM-IV diagnosis; eligible diagnoses included generalized anxiety disorder, social phobia, and panic disorder, and the follow-up post hoc tests found no difference in STAI-G change between participants with and without a formal GAD diagnosis (P = 0.35 and P = 0.65). The primary endpoint was a self-reported questionnaire, and the follow-up authors state that no objective, interview-based data and no measure of expectancy were collected. The placebo-first group had higher symptom ratings at inclusion, a difference that remained throughout the trial.
Each participant received LSD 200 μg in two sessions of approximately 12 hours with one investigator or therapist, and study visits included talk therapy. The follow-up publication describes the study drug as LSD free base in an oral solution of 96% ethanol (100 μg per mL) with an ethanol-only placebo, while the registry describes placebo capsules containing mannitol. Most participants had received anxiolytics, antidepressants, or psychotherapy before entry, antidepressants were tapered only for the sessions, and the authors state that LSD served as an add-on treatment; the participants were described as having a long history of treatment attempts and failures, with anxiety diagnosed a mean of 10 years before inclusion.
The 12-month follow-up had no control group, since all participants had received LSD by then. Questionnaires were returned by mail by 35 participants, with 33 contributing STAI measures, and 6 participants continued psychedelic therapy in the Swiss limited-use programme with one to four additional LSD sessions. The authors state that it is largely unclear what therapy participants received between the end-of-study visit and follow-up. The primary publication reports transient, mild acute untoward effects in 8 participants (19%) and one treatment-related serious adverse event of acute transient anxiety (2%), which the company announcement describes as acute transient anxiety and delusions. The registry has no posted results.
Two authors are consultants for Mind Medicine, Inc., which licensed the knowhow and data owned by University Hospital Basel; the authors state that the company had no role in financing, planning, or conducting the follow-up study, and the company states that it has exclusive access and rights to the data.
Limitations stated by the authors of the follow-up
“The present study also has limitations. The present analysis included no control group for long-term effects of LSD. Additionally, no objective, interview-based data were collected, the herein-reported data are based on self-report questionnaires and no measure of expectancy was collected. All participants received LSD within this crossover study. Lasting effects were compared with measures before LSD-assisted therapy over time and within subjects. Therefore, we cannot exclude the possibility that other factors contributed to the long-term effects. Furthermore, it is largely unclear what therapy people received between the end-of-study visit and the follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment expectancy and differences between sequence groups
“However, it remains unclear why individuals in the LSD-first group appeared to benefit more from LSD-assisted therapy compared with those who received placebo first.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This also raises a question about treatment expectancy and whether people in the placebo-first group felt disadvantaged by not receiving LSD in the first period and whether this motive remained intact and influenced the subsequent therapeutic response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Also, the two placebo sessions in the second period could have served as additional integration sessions in those who received LSD in the first period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Additional sessions outside the trial
“There was no significant difference in the primary treatment outcome (STAI-G) at follow-up compared with those who had no further psychedelic-assisted therapy, although an important consideration is the small sample size (n = 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
LDA1
Objective
Registered purpose
Published objective
“A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present LSD study was designed to evaluate previous findings applying current research methodology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Objective of the qualitative follow-up
“Participants of this study were included in a prospective follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study identifiers, dates, and status
| Item | Registry record |
|---|---|
| Other study ID | “LDA1” |
| Phase | “Phase 2” |
| Study start | “2008-02” |
| Primary completion (actual) | “2011-04-14” |
| Study completion (actual) | “2012-09” |
| First posted (estimated) | “2009-06-15” |
| Results first posted | “2021-12-08” |
| Last update posted | “2023-07-12” |
Site: one private practice in Switzerland
Study design
Official title and registered design
| Design element | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
Active placebo control and open-label crossover
“This phase 2 double-blind, active placebo-controlled, randomized clinical trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two months after the second experimental session, a follow-up evaluation was completed, and the treatment period was finished by breaking the blind for each individual. The participants who received the active placebo could cross over to an identical but open-label treatment with 200 μg of LSD. A long-term follow-up evaluation was conducted 12 months after the last experimental session with LSD in either the blinded portion of the study or the open-label crossover.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ethics and regulatory approvals
“was approved by the Ethics Committee of the Canton of Aargau, Swissmedic, the Swiss Federal Office for Public Health (Bundesamt fuer Gesundheit [Swiss Ministry of Health]), and the US Food and Drug Administration (Investigational New Drug no. 101,825) and was conducted in accordance with Good Clinical Practices.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Funding and sponsor
“This study was funded in part by Schweizerische Aerztegesellschaft für Psycholytische Therapie (Swiss Medical Society for Psycholytic Therapy) and Multidisciplinary Association for Psychedelic Studies. Rick Doblin (president) and Berra Yazar-Klosinski are employees of the main sponsor MAPS. Peter Gasser is president of SAEPT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria
Exclusion criteria
Eligibility as published: STAI threshold and exclusions
“Individuals with current alcohol or drug dependence (except caffeine or nicotine); primary psychotic, bipolar I affective, or dissociative disorders; and neurocognitive impairment and women who were pregnant or nursing were excluded from this study. All participants reported a score of greater than 40 on either the state or the trait scale of the Spielberger State-Trait Anxiety Inventory” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recruitment
Treatment
Registered treatment arms
Study drug: LSD free base capsules
“LSD was supplied as free base by Lipomed (Arlesheim, Switzerland). Capsules consisting of 200 μg (experimental dose) and 20 μg of LSD (active placebo) were prepared by Bichsel Laboratories (Interlaken, Switzerland).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Capsules were of identical size, color, and shape and were bottled in sequentially numbered containers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Experimental sessions and dose selection
“The primary intervention consisted of two full-day experimental sessions scheduled 2 to 3 weeks apart with a male/female co-therapist team, embedded within an ongoing process of drug-free psychotherapy sessions for preparatory and integrative purposes. The participants were randomly assigned to the experimental dose groups, receiving either an oral dose of 200 μg of LSD (n = 8) or an active placebo of 20 μg of LSD (n = 4). The experimental dose was a moderate amount expected to produce the full spectrum of a typical LSD experience, without fully dissolving normal ego structures. The 20-μg dose of LSD was chosen as an active placebo to produce short-lived, mild, and detectable LSD effects that would not substantially facilitate a therapeutic process.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Session setting, duration, and psychotherapy
“Two preparatory psychotherapy sessions served to discuss the participant’s history, social situation, personality, health, mind-set, and emotional situation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other than going to the bathroom, the participants remained in the treatment room for the entire 8-hour experimental session and overnight with an attendant nearby.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The therapeutic session ended after 8 hours, when the acute effects had subsided, followed by a brief review of the day’s experiences. After each experimental session, three drug-free psychotherapy sessions lasting 60 to 90 minutes took place, during which the participant’s experiences were reviewed for integration and deepening the therapeutic process.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant medications and restrictions
“The participants were required to taper off of antidepressants and antianxiety medications, to avoid alcohol and recreational drugs for 24 hours before, and to abstain from driving for 24 hours after the experimental sessions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the study, two participants (both experimental dose) received concomitant selective serotonin reuptake inhibitor (SSRI) treatment for depression and tapered off of these medications five half-lives before each experimental session because SSRIs may attenuate the effects of the serotonergically active experimental drug” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three participants received benzodiazepines (two experimental dose and one active placebo) as needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using State-Trait anxiety inventory score as the primary endpoint
STAI as the primary outcome measure
“The STAI Form X, a widely used self-report instrument for assessing state and trait anxiety in adults, served as the primary outcome measure of anxiety symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcome measures were completed at baseline, 1 week after experimental sessions, 2-month follow-up, and 12-month follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered primary outcome and scale description
Secondary outcome measures
“Secondary outcome measures included the European Cancer Quality of Life Questionnaire 30-item version 1.0” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the SCL-90-R” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and the Hospital Anxiety and Depression Scale” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After each experimental session, the State of Consciousness Questionnaire was completed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Screened, enrolled, and randomized
“Of 70 participants who were evaluated for eligibility by telephone or e-mail, 20 were further screened in person, and 12 were enrolled in this study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The participants received either 200 μg of LSD (n = 8) or 20 μg of LSD with an open-label crossover to 200 μg of LSD after the initial blinded treatment was unmasked (n = 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analyzed: 8 and 3 participants
“One active placebo participant was excluded from analysis after completing all study procedures because of a correction in the diagnosis of the qualifying disease state, which no longer satisfied the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Values are mean ± SEM of changes from baseline in eight subjects in the LSD group and three subjects in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sample size basis
“As a pilot study, this study had limited sample size, which reduced precision in effect size estimates and significance testing. The sample size selected was sufficient for a study primarily focused on safety and feasibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants assessed at 12 months in the qualitative follow-up
Description of analysis sets
Statistical methods and multiplicity
“Repeated-measures analysis of variance (ANOVA) was used to test for significant changes in anxiety from baseline to subsequent posttreatment measurements. STAI trait and STAI state were analyzed in separate ANOVAs. To account for multiplicity, the alpha level indicating significance was adjusted to 0.025 (two tailed). Effect sizes were estimated using Cohen’s d techniques. Results of the 12-month follow-up were compared with those of the 2-month follow-up with paired t-tests. Secondary outcome measures conducted for exploratory purposes were not used for significance testing to reduce multiplicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Handling of missing data and exclusion from analysis
“We were unable to obtain results for two subjects (one experimental dose, one active placebo) from the assessment conducted 1 week after the second experimental session because of intervening cancer treatments. To avoid substantially reducing the sample size because of missing data, the assessment 1 week after the second experimental session was dropped for all subjects from analysis of outcomes. One active placebo participant was excluded from analysis after completing all study procedures because of a correction in the diagnosis of the qualifying disease state, which no longer satisfied the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Registry participant flow
Baseline characteristics
Registry baseline characteristics
| Characteristic | Full dose LSD (200 mcg) | Active placebo LSD (20 mcg) | Total |
|---|---|---|---|
| Participants | “8” | “3” | “11” |
| Age, years, mean (SD) | “49.6(8.4)” | “57.4(9.9)” | “51.7(9.1)” |
| Female | “3” | “1” | “4” |
| Male | “5” | “2” | “7” |
| History of suicidal tendencies: none | “8” | “1” | “9” |
| History of suicidal tendencies: mild | “0” | “2” | “2” |
| Metastatic breast carcinoma | “3” | “1” | “4” |
| Metastatic gastric carcinoma | “2” | “0” | “2” |
| Plasmocytoma | “1” | “0” | “1” |
| Non-Hodgkin's Lymphoma | “0” | “1” | “1” |
| Celiac Disease | “0” | “1” | “1” |
| Parkinson's Disease | “1” | “0” | “1” |
| Bechterew's Disease | “1” | “0” | “1” |
Baseline STAI scores (registry primary outcome at baseline, visit 4)
| STAI subscale, mean (SD) | Full dose LSD (200 mcg), n = 8 | Active placebo LSD (20 mcg), n = 3 |
|---|---|---|
| STAI-state | “53.1(4.7)” | “47.7(7.7)” |
| STAI-trait | “53.2(4.3)” | “43.3(7.0)” |
Race and ethnicity not collected
Diagnoses and prior LSD experience
“Eleven of the 12 subjects had no prior experience with LSD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“half of the subjects were diagnosed with generalized anxiety disorder (GAD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline comparability of STAI scores
“No significant difference was found (p = 0.261) between group mean scores at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant difference was found between the groups at baseline (p = 0.563).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Primary endpoint: STAI at 2 months after the second session (registry)
| STAI subscale, mean (SD) | Full dose LSD (200 mcg), n = 8 | Active placebo LSD (20 mcg), n = 3 |
|---|---|---|
| STAI-state | “41.5(3.2)” | “51.7(5.3)” |
| STAI-trait | “45.2(3.7)” | “49.0(6.1)” |
Primary endpoint: published analysis
“At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trait anxiety
“The visit × group interaction testing for differences between the groups produced p = 0.033 (F = 4.151, df = 2,18), and observed statistical power was 65.6%, with results trending toward statistical significance. Comparing trait anxiety at baseline with 2-month follow-up yielded an effect size of 1.1. However, only three of eight experimental dose subjects dropped lower than the threshold value of 40 after the intervention. In contrast, all active placebo subjects experienced increases in trait anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
State anxiety
“The visit × group interaction testing for differences between the groups produced p = 0.021 (F = 4.846, df = 2,18), and observed statistical power was 72.7%. Even controlling for multiplicity, the reductions in state anxiety were statistically significant 2 months after two experimental sessions of LSD-assisted psychotherapy. Comparing state anxiety at baseline with 2-month follow-up yielded an effect size of 1.2. However, only three of eight experimental dose subjects dropped lower than the diagnostic cutoff of 40 after the intervention. In contrast, two active placebo subjects experienced increases in state anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Durability at 12 months
“Comparison of 2-month and 12-month follow-up results in the subjects who received 200 μg of LSD in either the blinded sessions or the open-label crossover indicate that the benefits were sustained over time. The mean difference varied only by 0.667 between these assessments, and no significant difference was found with p = 0.825 (two tailed).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparison of 2-month and 12-month follow-up results in the subjects who received 200 μg of LSD in either the blinded sessions or the open-label crossover indicates that the benefits were sustained over time. The mean difference varied only by 1.00 between these assessments, and no significant difference was found with p = 0.531 (two tailed).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospital Anxiety and Depression Scale
“The experimental dose group mean (SD) anxiety scores decreased from 11.7 (3.4) to 8.1 (3.2) after two sessions, whereas the active placebo group anxiety scores decreased only from 11.3 (2.1) to 10.7 (3.0). The active placebo subjects who continued to the crossover experienced an even greater decline lower than the diagnostic cutoff for anxiety to 7.0 (2.6). All subjects who received the experimental dose were lower than the diagnostic cutoff at the 12-month follow-up, with a mean (SD) of 7.6 (4.5). The depression results also mirrored the anxiety results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Quality of life: EORTC-QLQ global health score
“Global health scores from the EORTC-QLQ increased from a mean (SD) of 37.4 (10.0) at baseline to 50.0 (14.9) after treatment with two sessions of 200 μg of LSD, whereas mean scores decreased from 44.3 (12.7) to 36.0 (12.8) in the active placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
General psychopathology: SCL-90-R Global Severity Index
“Global Severity Index (GSI) scores from the SCL-90-R decreased from a mean (SD) T-score of 69.6 (6.7) at baseline to 60.2 (7.2) in the experimental dose group whereas increasing from 66.0 (15.1) to 67.7 (10.2) in the active placebo group. The active placebo group experienced an improvement comparable with the full-dose group after receiving the experimental dose in the open-label crossover, with mean (SD) T-scores dropping to 57.3 (15.0).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participant-reported changes at 12 months (qualitative content analysis)
Safety results
Severe and related adverse events as published
“Neither the experimental dose (200 μg of LSD) nor the active placebo (20 μg of LSD) produced any drug-related severe adverse events, that is, no panic reaction, no suicidal crisis or psychotic state, and no medical or psychiatric emergencies requiring hospitalization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The experimental dose subjects experienced more types of AEs (n = 18) than the active placebo subjects (n = 8). In general, AEs were reported more frequently and with increased intensity in the experimental dose sessions. Interestingly, fewer reports of anxiety were received during experimental sessions with 200 μg (22.7%) than with active placebo (50%), and the mean intensity of anxiety was comparable between the groups. However, the subjects reported experiencing mild-to-moderate emotional distress similarly in experimental dose sessions (36.4%) and active placebo sessions (33.3%). Most AEs resolved when drug effects diminished. Only six reports of mild related AEs (illusions, feeling cold or abnormal, and some emotional distress) persisted until the next day. No flashback phenomena or other prolonged effects were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vital signs and rescue medication
“LSD did not significantly alter blood pressure or heart rate” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three participants received pain medication during the study, only one of which was required as rescue medication for a treatment-emergent AE. Acetaminophen was required for this participant for a moderate headache the day after an experimental dose session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry adverse events: mortality, serious, and selected other adverse events
| Adverse event (affected / at risk) | Full dose LSD (200 mcg), stage 1 | Active placebo LSD (20 mcg), stage 1 | Full dose LSD (200 mcg), stage 2 |
|---|---|---|---|
| All-cause mortality | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Serious adverse events, total | “1/8 (12.50%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Serious: metastatic esophageal cancer | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Serious: pyelonephritis | “0/8 (0.00%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Other adverse events, total | “8/8 (100.00%)” | “4/4 (100.00%)” | “3/3 (100.00%)” |
| Feeling cold | “6/8 (75.00%)” | “0/4 (0.00%)” | “1/3 (33.33%)” |
| Illusions | “6/8 (75.00%)” | “1/4 (25.00%)” | “2/3 (66.67%)” |
| Emotional distress | “5/8 (62.50%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Feeling abnormal | “5/8 (62.50%)” | “2/4 (50.00%)” | “1/3 (33.33%)” |
| Time perception altered | “4/8 (50.00%)” | “0/4 (0.00%)” | “2/3 (66.67%)” |
| Mydriasis | “3/8 (37.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Anxiety | “2/8 (25.00%)” | “2/4 (50.00%)” | “1/3 (33.33%)” |
| Impaired gait | “2/8 (25.00%)” | “0/4 (0.00%)” | “2/3 (66.67%)” |
| Hallucination | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
Study limitations
Summary
LDA1 was a phase 2 pilot trial at one private practice in Solothurn, Switzerland, with the Multidisciplinary Association for Psychedelic Studies (MAPS) named as main sponsor; MAPS co-funded the trial, and the funding statement names two MAPS employees. Twelve participants with anxiety associated with life-threatening diseases were randomized to LSD 200 μg (8 participants) or an active placebo of LSD 20 μg (4 participants); one active placebo participant was excluded from analysis after a correction of the qualifying diagnosis, leaving 8 and 3 participants. The authors state that the sample size was sufficient for a study primarily focused on safety and feasibility and that the limited sample reduced precision in effect size estimates and significance testing.
With the alpha level adjusted to 0.025 for multiplicity, the reduction in state anxiety (p = 0.021) met the threshold and the reduction in trait anxiety (p = 0.033) did not. Only three of eight participants in the 200 μg group fell below the threshold of 40 on each subscale. The assessment 1 week after the second session was dropped for all participants because results were missing for two participants, and secondary outcomes were not tested for significance. The 12-month comparisons included participants who received 200 μg in the open-label crossover and had no concurrent control, and the qualitative follow-up tested 10 participants.
Blinding was not maintained: for all 24 blinded sessions, all participants correctly guessed the dose, and the authors state that the 20-μg dose was too low to achieve uncertainty about the dose. Half of the participants received a SCID diagnosis of generalized anxiety disorder, and the authors state that this does not mean the participants had the conventional pattern of psychopathology usually associated with GAD, because the SCID items do not differentiate GAD from a reaction to a life-threatening disease. The registry lists the illnesses as metastatic breast carcinoma (4 participants), metastatic gastric carcinoma (2), and plasmocytoma, non-Hodgkin's lymphoma, celiac disease, Parkinson's disease, and Bechterew's disease (1 each); mean age was 51.7 years, 7 of 11 participants were male, and race and ethnicity were not collected. The authors state that the course of the somatic illness may affect psychological parameters independent of the intervention, and that the EORTC-QLQ focused on physical aspects and was insufficient for evaluating long-term psychological changes.
The intervention combined LSD capsules with two preparatory psychotherapy sessions, three drug-free integrative psychotherapy sessions after each experimental session, and a male and female co-therapist team, with 8-hour experimental sessions and an overnight stay. The publication reports no drug-related severe adverse events; the registry reports serious adverse events of metastatic esophageal cancer (1 of 8) and pyelonephritis (1 of 4) and all-cause mortality of 1 of 8 in the 200 μg group. The registry and the publication differ on two details: the registry requires a score of at least 40 on each part of the STAI and spaces sessions two to four weeks apart, while the publication states that participants scored greater than 40 on either the state or the trait scale and that sessions were 2 to 3 weeks apart.
Limitations stated by the authors: sample size, blinding, and dose
“As a pilot study, this study had limited sample size, which reduced precision in effect size estimates and significance testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The imperfect blinding also limits the validity of the results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although using a slightly higher LSD dose in the comparator group can increase blinding, it can also increase efficacy of the comparator, compromising the estimates of effect size. Given the safety of the moderate experimental dose, results might have been improved with a larger dose of 250 μg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding assessment
“For all 24 blinded sessions, all participants correctly guessed the dose of LSD that was administered, and both therapists guessed incorrectly in one active placebo session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This indicates that the 20-μg dose was too low to achieve successful uncertainty about the dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations stated by the authors: somatic illness and quality of life measure
“Other limitations exist in treating participants with grave somatic diseases because the course of the somatic illness (e.g., worsening or improving) may substantially impact psychological parameters independent of the therapeutic intervention and contribute to missing data. The quality of life questionnaire (EORTC-QLQ), which was chosen as a secondary outcome measure, focuses extensively on physical aspects and was insufficient for evaluating long-term psychological changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Applicability of the GAD diagnosis
“Neither the SCID’s five items about GAD nor criterion E for GAD in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, differentiates between anxiety typically seen with GAD and a reaction to a life-threatening disease (and its consequences). Therefore, even though the SCID generates a diagnosis of GAD, this does not mean that the subjects had the conventional pattern of psychopathology usually associated with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of sessions
“Most of the participants stated a preference for more than two LSD sessions and a longer treatment period. The results demonstrated a decrease in STAI scores most prominently after the second LSD session, suggesting that at least two LSD sessions are needed to demonstrate these effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MM-120-101
Objective
Comparison of the phase 2b capsule with the phase 3 orally disintegrating tablet
Purpose of the bridging study stated in the annual report
Location and study date
Registry record
| Item | Registry record |
|---|---|
| Scientific title | “Phase I trial: MM-120-101” |
| IRAS number | “1007602” |
| Sponsor | “Mind Medicine Inc” |
| Countries of recruitment | “United Kingdom” |
| Participating centre | “MAC Clinical Research Liverpool” |
| Participating centre | “MAC Clinical Research Manchester” |
| Date of first enrolment | “13/10/2023” |
| Date of final enrolment | “04/12/2023” |
| Completion date | “19/12/2023” |
| Overall study status | “Deferred” |
Ethics approval
| Item | Research summary |
|---|---|
| REC name | “Wales REC 1” |
| REC reference | “23/WA/0112” |
| Date of REC opinion | “1 Sep 2023” |
| REC opinion | “Further Information Favourable Opinion” |
Deferred publication of registry details
Study design
Open-label, randomized, two-period crossover design
Study schedule
| Period | Quoted study day |
|---|---|
| Screening | “-21 to -1” |
| Washout | “2-13” |
| Follow-up | “15-29” |
Registry design description
| Item | Registry record |
|---|---|
| Study design | “Phase 1 study in 30 healthy volunteers” |
| Primary study design | “Other” |
| Phase | “Phase I” |
| Intervention type | “Drug” |
Assessments: plasma pharmacokinetics, subjective effects, and adverse events
Eligibility criteria
Entry criteria
| Criterion | Quoted entry criterion |
|---|---|
| Sex | “Men and Women” |
| Age | “Ages 18-55” |
| Health status | “Healthy volunteers” |
| Medications | “No prohibited medications” |
Registry eligibility fields
| Item | Registry record |
|---|---|
| Participant type | “Healthy volunteer” |
| Age group | “Adult” |
| Sex | “All” |
| Health condition studied | “Healthy volunteers” |
Treatment
Four 25 µg capsules and one 100 µg orally disintegrating tablet, in randomized sequence
Formulations named in the study schematic
Study outcomes
Rationale for using plasma pharmacokinetic parameters as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size
| Item | Registry record |
|---|---|
| Target sample size at registration | “30” |
Description of analysis sets
Analysis methods
Safety analysis set in the pooled safety analysis
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
Pharmacokinetic comparison: abstract results
Geometric mean ratios relative to the capsule
| Parameter | Quoted geometric mean ratio |
|---|---|
| Cmax | “GMR: 1.02” |
| AUC0-∞ | “GMR: 1.17” |
Company-derived comparisons and their bases, March 2024
“50% faster onset of action” (opens the source at this quote in a new tab)
“17% improved bioavailability” (opens the source at this quote in a new tab)
“23% increase in AUC at target conc.” (opens the source at this quote in a new tab)
“Reduced GI side effects” (opens the source at this quote in a new tab)
Health-related quality of life and patient-reported outcomes
Subjective drug effects on visual analogue scales
Safety results
Treatment-emergent adverse events by formulation: abstract
Treatment-emergent adverse events in the pooled safety poster
| Measure | Phase 1 PK bioavailability study, DT120 ODT (n = 29) |
|---|---|
| Any TEAE | “25 (86.2)” |
| Mild | “15 (51.7)” |
| Moderate | “9 (31.0)” |
| Severe | “1 (3.4)” |
Serious adverse events, suicidality, and vital signs across the four pooled studies
Study limitations
Summary
MM-120-101 was an open-label, randomized, two-period crossover study in healthy adults aged 18 to 55 years; it measured plasma pharmacokinetics, subjective effects, and adverse events, and enrolled no participants with GAD. Of 30 planned participants, 29 were randomized and 24 received both formulations; the pharmacokinetic analysis used those 24. Each formulation was given once at 100 µg, so the study does not inform repeated dosing or other dose levels.
Results come from an abstract, company presentations, and a safety analysis across four DT120 studies; publication of the registry record's full details is deferred to 19/12/2028. Sources differ on the pharmacokinetic summary: the abstract reports Cmax as similar, an AUC geometric mean ratio 16% higher with the ODT, and bioavailability similar to the capsule, while a company presentation describes 17% improved bioavailability (a geometric mean ratio of 1.17), a 23% increase in AUC at target concentration, and reduced gastrointestinal side effects based on a comparison between the phase 2b capsule study and this study. Sources also differ on adverse events with the ODT: the abstract reports 23 participants (79.3%) with TEAEs after the ODT, and the pooled safety poster reports 25 (86.2%) in a column labeled DT120 ODT (n = 29). The company's annual report states that the bridging study was completed in 2024, while the registry gives a completion date of 19/12/2023. The annual report states that the change in formulation could cause the product to perform differently, and one author names formulation bridging among the conditions on which adoption will depend.
Risk stated by the company from the change in formulation
Formulation bridging named as a condition for adoption
“Adoption will depend on full peer-reviewed reporting of the positive Voyage and Panorama phase 3 topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable monitored-care model.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote